Eupraxia Pharmaceuticals Inc
NASDAQ:EPRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Eupraxia Pharmaceuticals Inc
Net Income (Common)
Eupraxia Pharmaceuticals Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Net Income (Common)
-CA$38.6m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Net Income (Common)
-CA$12.2m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-91%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Net Income (Common)
$287.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Net Income (Common)
-$345.9m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-65%
|
CAGR 10-Years
-36%
|
|
|
Spectral Medical Inc
TSX:EDT
|
Net Income (Common)
-CA$47.7m
|
CAGR 3-Years
-62%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-17%
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Net Income (Common)
-$117.3m
|
CAGR 3-Years
-59%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Eupraxia Pharmaceuticals Inc
Glance View
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia. The company went IPO on 2021-03-09. The firm's lead product candidate EP-104IAR, is developed for the treatment long-lasting pain relief for knee osteoarthritis (OA). In addition to EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. The firm's pipeline candidates include a range of drugs for indications such as post-surgical anesthetic (EP-105) and post-surgical site infections (EP-201). The firm is also engaged in the development of candidates to its pipeline including an internally developed oncology product. The firm is also engaged in developing a formulation of EP-104IAR for use in canine and equine OA.
See Also
What is Eupraxia Pharmaceuticals Inc's Net Income (Common)?
Net Income (Common)
-38.6m
CAD
Based on the financial report for Dec 31, 2025, Eupraxia Pharmaceuticals Inc's Net Income (Common) amounts to -38.6m CAD.
What is Eupraxia Pharmaceuticals Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-57%
Over the last year, the Net Income (Common) growth was -51%. The average annual Net Income (Common) growth rates for Eupraxia Pharmaceuticals Inc have been -18% over the past three years , -57% over the past five years .
